PIPELINE

In addition to its discovery-stage FMRP program, Opna’s lead clinical compound, OPN-2853, a bromo and extra terminal (BET) domain inhibitor, is currently in a Phase 1/2 trial with ruxolitinib (Jakafi®) in myelofibrosis, a chronic bone marrow disorder. The company also expects to initiate a Phase 2 study with OPN-7486, a colony stimulating factor 1 (CSF1) receptor inhibitor, in the first half of 2024.

Program

Target

Hit identification

Lead optimization

Preclinical

Phase 1

Phase 2

Hit identification

Lead optimization

Preclinical

Phase 1

Phase 2

OPN-2853
Target: BET

BET Inhibitor

OPN-2853 is a differentiated BET bromodomain inhibitor in Phase 2 clinical trials in combination with ruxolitinib for the treatment of myelofibrosis.

Explore

Hit identification

Lead optimization

Preclinical

Phase 1

Phase 2

OPN-7486
Target: CSF1R/TRK

Dual Inhibitor
of CSF1R and TRK

OPN-7486 inhibits recruitment of pro-tumorigenic TAMs and enables immune response to tumors by blocking the CSF1R/CSF1 interaction

Explore

Hit identification

Lead optimization

Preclinical

Phase 1

Phase 2

OPN-6602
Target: EP300/CREBBP

Dual Inhibitor
of EP300 and CREBBP

EP300 AND CREBBP OPN-6602, a dual inhibitor of EP300 and CBP, is a candidate therapy for cancers such as prostate cancer, leukemias and multiple myeloma.

Explore

Hit identification

Lead optimization

Preclinical

Phase 1

Phase 2

OPN-9627
Target: CD73

CD73 Inhibitor

Opna’s differentiated class of orally bioavailable, small molecule CD73 inhibitors, provide an immune-oncology opportunity in several tumor types.

Explore

Hit identification

Lead optimization

Preclinical

Phase 1

Phase 2

OPN-TEAD
Target: TEAD

TEAD Inhibitor

TEAD inhibitors provide a compelling treatment strategy in cancers with dysregulation in the Hippo Pathway.

Explore

Hit identification

Lead optimization

Preclinical

Phase 1

Phase 2

OPN-FMRP
Target: FMRP

FMRP Inhibitor

FMRP inhibition unlocks tumors to immune attack.

Explore